• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Topical and Systemic Retinoids in the Management of Hidradenitis Suppurativa: A Comprehensive Literature Review.外用和全身性维甲酸类药物治疗化脓性汗腺炎:一项全面的文献综述
Dermatol Ther (Heidelb). 2024 May;14(5):1079-1091. doi: 10.1007/s13555-024-01169-1. Epub 2024 May 3.
2
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
3
Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New?非生物疗法治疗化脓性汗腺炎的医学管理:有哪些新进展?
Am J Clin Dermatol. 2022 Mar;23(2):167-176. doi: 10.1007/s40257-021-00667-8. Epub 2022 Jan 6.
4
Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study.阿维A治疗化脓性汗腺炎的有效性和安全性、临床反应的预测因素:一项队列研究
Dermatology. 2023;239(1):52-59. doi: 10.1159/000526019. Epub 2022 Aug 23.
5
Radiotherapy for Hidradenitis Suppurativa: A Systematic Review.放射性疗法治疗化脓性汗腺炎:系统评价。
Dermatology. 2021;237(3):357-364. doi: 10.1159/000514027. Epub 2021 Feb 3.
6
Bimekizumab for the treatment of hidradenitis suppurativa.比美吉珠单抗治疗化脓性汗腺炎。
Immunotherapy. 2024;16(16-17):1005-1013. doi: 10.1080/1750743X.2024.2401308. Epub 2024 Sep 19.
7
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel.如何将手术与生物制剂靶向治疗相结合治疗化脓性汗腺炎的指南:来自意大利专家小组的德尔菲共识声明
Dermatology. 2024;240(5-6):885-896. doi: 10.1159/000539264. Epub 2024 Jul 18.
8
Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review.系统治疗法用免疫抑制剂和类视黄醇在化脓性汗腺炎中:系统评价。
Br J Dermatol. 2013 Feb;168(2):243-52. doi: 10.1111/bjd.12104.
9
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.化脓性汗腺炎的全身抗生素治疗:治疗现状与当前问题综述
Antibiotics (Basel). 2023 May 29;12(6):978. doi: 10.3390/antibiotics12060978.
10
Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.化脓性汗腺炎:基于350多名化脓性汗腺炎患者对可能的药物治疗的实用综述
Dermatol Online J. 2013 Apr 15;19(4):1.

引用本文的文献

1
Current Treatments and Future Directions for Hidradenitis Suppurativa: a Narrative Review of Completed and Ongoing Phase 3 Clinical Trials of Biologic Therapies.化脓性汗腺炎的当前治疗方法与未来方向:生物疗法已完成及正在进行的3期临床试验的叙述性综述
Dermatol Ther (Heidelb). 2025 Jul 18. doi: 10.1007/s13555-025-01487-y.
2
Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.平衡疗效与肝毒性:银屑病治疗中口服药物的综合综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 25. doi: 10.1007/s00210-025-04334-1.
3
Causal roles of skin and gut microbiota in skin appendage disorders suggested by genetic study.遗传研究提示皮肤和肠道微生物群在皮肤附属器疾病中的因果作用。
Front Immunol. 2024 Sep 10;15:1427276. doi: 10.3389/fimmu.2024.1427276. eCollection 2024.

本文引用的文献

1
Secukinumab in the treatment of hidradenitis suppurativa.司库奇尤单抗治疗化脓性汗腺炎。
Immunotherapy. 2023 Dec;15(17):1449-1457. doi: 10.2217/imt-2023-0103. Epub 2023 Oct 16.
2
Systemic Antibiotic Therapy in Hidradenitis Suppurativa: A Review on Treatment Landscape and Current Issues.化脓性汗腺炎的全身抗生素治疗:治疗现状与当前问题综述
Antibiotics (Basel). 2023 May 29;12(6):978. doi: 10.3390/antibiotics12060978.
3
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
4
Treatment response to isotretinoin correlates with specific shifts in Cutibacterium acnes strain composition within the follicular microbiome.异维 A 酸治疗反应与毛囊微生物组中痤疮丙酸杆菌菌株组成的特定变化相关。
Exp Dermatol. 2023 Jul;32(7):955-964. doi: 10.1111/exd.14798. Epub 2023 Mar 31.
5
The Effects of Acitretin on Insulin Resistance, Glucose Metabolism, and Lipid Levels in Patients with Psoriasis.阿维A对银屑病患者胰岛素抵抗、糖代谢及血脂水平的影响
Indian J Dermatol. 2022 Jul-Aug;67(4):349-354. doi: 10.4103/ijd.ijd_328_21.
6
The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa.达巴万星治疗中度至重度化脓性汗腺炎的疗效
Antibiotics (Basel). 2022 Nov 8;11(11):1573. doi: 10.3390/antibiotics11111573.
7
Acitretin plus macrolides and acitretin monotherapy in the management of hidradenitis suppurativa.阿维A联合大环内酯类药物与阿维A单药治疗化脓性汗腺炎
J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e392-e394. doi: 10.1111/jdv.18706. Epub 2022 Nov 5.
8
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study.口服维 A 酸治疗化脓性汗腺炎的药物生存情况:一项真实世界队列研究。
Am J Clin Dermatol. 2022 Nov;23(6):905-914. doi: 10.1007/s40257-022-00725-9. Epub 2022 Sep 7.
9
Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study.阿维A治疗化脓性汗腺炎的有效性和安全性、临床反应的预测因素:一项队列研究
Dermatology. 2023;239(1):52-59. doi: 10.1159/000526019. Epub 2022 Aug 23.
10
Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.局部使用 15%间苯二酚与 1%克林霉素治疗轻中度化脓性汗腺炎的疗效和安全性:一项回顾性研究。
Dermatol Ther. 2022 Jun;35(6):e15439. doi: 10.1111/dth.15439. Epub 2022 Mar 18.

外用和全身性维甲酸类药物治疗化脓性汗腺炎:一项全面的文献综述

Topical and Systemic Retinoids in the Management of Hidradenitis Suppurativa: A Comprehensive Literature Review.

作者信息

Molinelli Elisa, Gioacchini Helena, Marani Andrea, Rizzetto Giulio, Gambini Daisy, De Simoni Edoardo, Offidani Annamaria, Simonetti Oriana

机构信息

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

出版信息

Dermatol Ther (Heidelb). 2024 May;14(5):1079-1091. doi: 10.1007/s13555-024-01169-1. Epub 2024 May 3.

DOI:10.1007/s13555-024-01169-1
PMID:38700645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11116334/
Abstract

Hidradenitis suppurativa (HS) is a debilitating chronic skin disorder characterized by painful inflammatory nodules, abscesses and sinus tracts involving intertriginous areas and has an adverse impact on patient quality of life. Over the past decade, the therapeutic options of HS have increased significantly to comprise multiple modalities, including topical medication, systemic therapies (mainly antibiotics, retinoids, and biologics), surgical approaches, and lifestyle modifications. Biologics alone or in combination with surgery remain the treatment of choice for moderate to severe disease. However, non-biologic therapies (including retinoids) may be used as monotherapy for mild disease and in combination with biologics and surgical treatment in moderate to severe disease. Retinoids, specifically isotretinoin, acitretin, and alitretinoin, are historically used in the management of HS, supported by anecdotal evidence and with variable treatment response. Although the current American and European guidelines offer different recommendations on the use of retinoids in HS, retinoids remain a valuable ally in HS management. This review provides a comprehensive analysis of the current scientific literature on retinoid therapy (topical and systemic) in HS, highlighting disparities in mechanisms of action, efficacy, and safety to clarify their role in HS treatment.

摘要

化脓性汗腺炎(HS)是一种使人衰弱的慢性皮肤疾病,其特征为累及皮肤褶皱部位的疼痛性炎性结节、脓肿和窦道,对患者的生活质量产生不利影响。在过去十年中,HS的治疗选择显著增加,涵盖多种方式,包括局部用药、全身治疗(主要是抗生素、维甲酸类药物和生物制剂)、手术方法以及生活方式改变。生物制剂单独使用或与手术联合使用仍然是中重度疾病的首选治疗方法。然而,非生物治疗(包括维甲酸类药物)可用于轻度疾病的单一治疗,以及中重度疾病与生物制剂和手术治疗联合使用。维甲酸类药物,特别是异维甲酸、阿维A和阿利维A酸,长期以来一直用于HS的治疗,有轶事证据支持,但治疗反应不一。尽管目前美国和欧洲的指南对HS中维甲酸类药物的使用给出了不同建议,但维甲酸类药物仍然是HS治疗中的重要辅助手段。本综述对目前关于HS中维甲酸类药物治疗(局部和全身)的科学文献进行了全面分析,突出了作用机制、疗效和安全性方面的差异,以阐明它们在HS治疗中的作用。